BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients

European Journal of Human Genetics

Volumn 9, Issue 6, 2001, Pages 424-430

  Sarantaus, Laura ^a   Vahteristo, Pia ^a   Bloom, Elizabeth ^a   Tamminen, Anitta ^a   Unkila Kallio, Leila ^a   Butzow, Ralf ^a   Nevanlinna, Heli ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

BRCA1; BRCA2; Finland; Founder mutations; Ovarian carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FINLAND; FOUNDER EFFECT; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GERM LINE; HEREDITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; OVARY CARCINOMA; PATIENT REFERRAL; POPULATION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SYNDROME;

BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA; COHORT STUDIES; FAMILY HEALTH; FEMALE; FINLAND; FOUNDER EFFECT; HUMANS; LOGISTIC MODELS; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

FALLOPIA;

EID: 0034948376     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5200652     Document Type: Article

References (44)

1. Breast and ovarian cancer incidence in BRCA1-mutation carriers
2. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
3. Breast cancer genes-what are the real risks?
4. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
5. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
6. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation
7. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene
8. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer
9. Frequency of germline and somatic BRCA1 mutations in ovarian cancer
10. Contribution of BRCA1 mutations to ovarian cancer
11. Germline BRCA1 alterations in a population-based series of ovarian cancer cases
12. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary
13. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing
14. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients
15. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history
16. Mutations of the BRCA2 gene in ovarian carcinomas
17. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families
18. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: Evidence for additional susceptibility genes
19. A low proportion of BRCA2 mutations in Finnish breast cancer families
20. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland
21. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients
22. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
23. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families
24. Rapid detection of BRCA1 mutations by the protein truncation test
25. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer
26. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
27. Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1
28. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden
29. Survival in familial. BRCA1-associated, and BRCA2-associated epithelial ovarian cancer
30. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
31. Genetic testing for cancer susceptibility, Adopted on February 20, 1996
32. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
33. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk
34. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
35. BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing
36. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas
37. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: No evidence for other ovarian cancer-susceptibility genes
38. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer
39. Genetic susceptibility to non-polyposis colorectal cancer
40. Clues to the pathogenesis of familial colorectal cancer
41. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
42. Comparison of serous and mucinous ovarian carcinomas: Distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4
43. Epithelial ovarian cancer: Impact of surgery and chemotherapy on survival during 1977-1990